

PS2.267**Pneumococcal vaccine in COPD patients**

I Poyato Zafra(1), Miguel Sola García(1), JA Marin Relaño(2)

(1) C. Salud El Valle, Unidad docente MFyC Jaén, Spain

(2) C. Salud Virgen de la Capilla, Unidad docente MFyC Jaén, Spain

Corresponding author: Dr Ignacio Poyato Zafra, C. S. El Valle, Unidad Docente MFyC Jaén, Jaén, Spain. E-mail: ignacio_poyato@hotmail.com

Pneumococcal disease is a prevalent condition that causes a high rate of morbidity and mortality in our environment. In our country, Spain, experts from over 20 societies have signed a consensus about pneumococcal vaccination. After reviewing our patients in primary health centers from Jaén, Spain, we have noticed that we are not following the scientist community. The mentioned document compares different possibilities of pneumococcal vaccines making a review of the latest researchs. COPD population is one of the addressed groups We have decided to work in this area and study how those COPD patients are treated. We have proposed a cross-sectional descriptive research with more than 800 patients selected as the study population. Our pilot study showed that only a few part of our patients receive the correct vaccination regardless of the vaccine type, for example most of the patients receive an underdose. Moreover we are gathering information about which vaccine is used in each patient (13 serotypes or 23 serotypes). Prevention programs about adequate vaccination states could be carried out with this information.